Biogen Inc. earnings overview

BIIB FY2026 Q1 · Calendar Q2 2026

Biogen Inc.

Biogen delivered a strong Q1 FY2026, beating consensus on both revenue ($2.48B vs $2.29B estimate) and EPS ($3.57 vs $3.05 estimate). Growth-product sales reached $850M, up 12% YoY, led by LEQEMBI and SKYCLARYS. The pending Apellis acquisition and a deep pipeline with multiple data readouts through 2027-2028 frame an execution-heavy year. Management reaffirmed guidance, signaling confidence in the current trajectory. The stock rose ~6% on the report with volume 1.8x baseline.